Compass Pathways

We’re thrilled to welcome Dana Sultan-Rothman, MBA as our new Vice President of Communications at Compass Pathways!  Dana brings over 20 years of global experience in communications, marketing and branding across various highly regulated industries, including the mental health and neurology sectors. Her expertise in driving purposeful and high-impact marketing and communications strategies will be essential as we continue to advance our mission to accelerate patient access to evidence-based innovation in mental health.  Welcome to the team, Dana! 

We are excited to welcome Eric Rasmussen as the new Vice President of Government Affairs & Public Policy at Compass Pathways! Eric brings over 20 years of experience working with federal policymakers, state governments, and patient advocacy groups to shape public policy and improve patient access to treatments. His expertise in legislative strategy, regulatory engagement, and advocacy leadership will be invaluable as we continue our mission towards evidence-based innovation. Welcome, Eric! 

Today we shared our Q4 and full-year 2024 financial results, highlighting the advancements we’re making in treatment-resistant depression (TRD) to bring a differentiated treatment option to those facing this devastating disease.     Read more, including important cautionary statements about forward-looking information, here: https://lnkd.in/eWqJf7KN

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

We are excited to share the publication of our latest paper describing the Compass Psychological Support Model (CPSM) in the American Journal of Psychiatry. Used in our clinical trials of psilocybin treatment for serious mental health conditions, the CPSM is designed to support the physical and psychological safeguarding of clinical trial participants. The paper outlines the key principles and methods of the CPSM, as well as the health care professional training, mentoring, and fidelity assessment programs developed to ensure the quality and consistency of the CPSM delivery in our clinical trials. For a quick video summary, see attached.    Congratulations to the authors on this achievement: Guy Goodwin, Alice Gaillard, Namik Kirlic, Don Koelpin, Ph.D., Nadav Liam Modlin, Ekaterina Malievskaia, Molly Lennard-Jones, Merve Atli, Stephanie Knatz Peck, Ph.D.

Compass Pathways is breaking barriers with psilocybin for treatment-resistant depression—and they’ve just secured $150m to keep pushing boundaries. 🚀💡 Excited to share a new episode of our podcast with Kabir Nath, CEO of Compass Pathways. Kabir and his team are doing transformative work in mental health, tackling some of the toughest challenges for patients with treatment-resistant depression. In this conversation, we dive into everything from the science behind psilocybin to the patient-centered approach Compass is taking to ensure safety, build trust, and create equitable access. A few takeaways from our conversation: - Psilocybin as a game-changer: Kabir explains why this compound could represent a paradigm shift in mental health care. - Patient-first innovation: The Compass team is laser-focused on safety, equity, and building trust with rigorous research to support vulnerable populations. - Beyond TRD: We dive into how psilocybin could help address other conditions like PTSD opening doors to a broader range of solutions in mental health.  🎧 Tune in now! Link in comments.

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Message from Kabir Nath (CEO):   Happy New Year! At Compass, we are excited to be kicking off 2025 with strong momentum, and I want to share my excitement for the year ahead. 2025 will be a critical year for Compass and we are looking forward to the first data readout from our phase 3 TRD program expected in the second quarter.    Our focus for 2025 is clear: delivering on our phase 3 TRD program and now, also accelerating a late-stage development program in PTSD, both areas of critical unmet need. We are inspired by the patients and their families who are waiting for better treatment options for these devastating conditions.      Here’s to a successful, impactful, and inspiring 2025!   Read more, including important cautionary statements about forward-looking information, here in our most recent quarterly report on Form 10-Q: https://lnkd.in/e6KxY23A

Compass Pathways Announces Pricing of Underwritten Offering